Startups
Prudentia Sciences
Prudentia Sciences develops an AI platform for scientific due diligence and valuation of drug assets. It combines clinical, regulatory and commercial evidence with scientific evaluation frameworks and financial models to help pharmaceutical companies, biotechnology companies and investors assess medicines for licensing, acquisition and investment. The platform supports evidence provenance and human review of AI-generated evaluations.
Team
Ben KleinHead of Partnerships |
David NicholsonScientific Advisory Board Member |
Joe von RickenbachBusiness Advisory Board Member |
John ReyndersHead of Strategy |
Mark G. CurrieChair, Scientific Advisory Board |
 Mary Lynne HedleyScientific Advisory Board Member |
Matt LeoniScientific Advisory Board Member |
Sadiqa MahmoodFounder and Chief Executive Officer |
Sean O'SheaChief Technology Officer |
Sharon TanScientific Lead |
Stuart ChaffeeBusiness Advisory Board Member |
Travis MayBusiness Advisory Board Member |